The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: -10.50 (-0.59%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,772.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
9th Sep 202012:47 pmRNSDirector/PDMR Shareholding
3rd Sep 20207:00 amRNSSanofi/GSK: Phase 1/2 trial of COVID-19 vaccine
1st Sep 20203:23 pmRNSTotal Voting Rights
13th Aug 202010:48 amRNSDirector/PDMR Shareholding
6th Aug 20207:00 amRNSUS FDA approves GSK’s BLENREP for multiple myeloma
3rd Aug 202011:31 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSSanofi/GSK to supply EU with 300m COVID 19 doses
31st Jul 202012:00 pmRNSSanofi & GSK picked for Op. Warp Speed by US Gov.
29th Jul 20202:02 pmRNSDirector/PDMR Shareholding
29th Jul 202012:00 pmRNS2nd Quarter Results
29th Jul 20207:00 amRNSSanofi and GSK agree UK doses of COVID-19 vaccine
28th Jul 20203:23 pmRNSDirector/PDMR Shareholding
24th Jul 20201:16 pmRNSGSK receives positive CHMP opinion for Belamaf
20th Jul 20207:00 amRNSGSK and CureVac enter collaboration
15th Jul 20209:31 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSFDA Panel Votes IN FAVOR of Belantamab mafodotin
14th Jul 20201:19 pmRNSDirector/PDMR Shareholding
13th Jul 20205:42 pmRNSDirector/PDMR Shareholding
10th Jul 20204:41 pmRNSDirector/PDMR Shareholding
10th Jul 20203:15 pmRNSDirector/PDMR Shareholding
10th Jul 20203:07 pmRNSDirector/PDMR Shareholding
1st Jul 202012:25 pmRNSTotal Voting Rights
29th Jun 20208:00 amRNSGSK’s daprodustat gains first regulatory approval
19th Jun 20203:22 pmRNSFDA Advisory Committee review belantamab mafodotin
18th Jun 202012:25 pmRNSDirector/PDMR Shareholding
16th Jun 202012:51 pmRNSDirector/PDMR Shareholding
11th Jun 20203:56 pmRNSDirector/PDMR Shareholding
9th Jun 20202:16 pmRNSDirector/PDMR Shareholding
1st Jun 202012:14 pmRNSTotal Voting Rights
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:37 pmRNSPrice Monitoring Extension
26th May 202011:53 amRNSBlock listing Interim Review
19th May 20205:51 pmRNSHolding(s) in Company
18th May 20207:09 amRNSViiV PrEP jab shows high efficacy over daily pill
13th May 20205:04 pmRNSDirector/PDMR Shareholding
11th May 20206:07 pmRNSDirector/PDMR Shareholding
7th May 20205:43 pmRNSPublication of Final Terms
7th May 20203:52 pmRNSDirector/PDMR Shareholding
7th May 20207:56 amRNSGSK sells its holding in Hindustan Unilever
6th May 20205:40 pmRNSResult of AGM
4th May 20206:00 pmRNSDirector/PDMR Shareholding
4th May 20205:40 pmRNSPublication of a Prospectus
4th May 20204:18 pmRNSRights attached to ordinary shares
1st May 20203:45 pmRNSTotal Voting Rights
30th Apr 20207:00 amRNSGSK’s Zejula approved in first-line ovarian cancer
29th Apr 202012:00 pmRNS1st Quarter Results
29th Apr 202011:00 amRNSArrangements for Shareholder Webcast
16th Apr 20203:25 pmRNSDirector/PDMR Shareholding
16th Apr 20202:21 pmRNSDirector/PDMR Shareholding
16th Apr 20201:49 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.